Company intelligence / Profile preview

OneSkin

San Francisco, California, United Statesoneskin.co ↗

Ownership: Private
Employees: ~33
Development stage: Other

Overview

OneSkin has developed a proprietary peptide-based topical product line led by the OS‑01 peptide. Clinical studies have shown that their lead product can reduce biological age of the skin, improve barrier function, increase collagen/hyaluronic acid production, and reduce visible signs of aging. Peer-reviewed data supports efficacy in both lab models and human clinical trials.

Therapeutic areas: Dermatology
Modalities: PeptidesTopical product
Industry: Non-Drug Biotech

Partnerships

IndieBio accelerator program participant

Beyond the preview

Go deeper on OneSkin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OneSkin.

Explore the full profile